Drug delivery, disposition and dynamics (D4)

Drug Delivery, Disposition and Dynamics

The Drug delivery, disposition and dynamics (D4) research teams within the Monash Institute of Pharmaceutical Sciences (MIPS) are designing and developing the next generation of drug delivery systems and anti-infective agents to enhance medicine effectiveness and patient treatment.

Ben Boyd

Research areas

Find a researcher



Contact us

+61 3 9903 9614
nicki.penny@monash.edu

Find a D4 PhD project

We're looking for the brightest biomedical science, pharmaceutical science and pharmacy talent to join our ambitious, curious and groundbreaking research teams. We want to change the world and you can help us.

See the latest news

Search news

Browse by category

Browse: ▾

Select all - Clear all
Nico Voelcker

MIPS researcher receives prestigious Humboldt Research Award

Professor Nicolas Voelcker from the Monash Institute of Pharmaceutical Sciences (MIPS) has received a Humboldt Research Award to the value of EUR 60,000 (approximately AUD $94,000).The award has been granted by Germany’s Alexander von Humboldt
Model diseased heart

Australian researchers drive global call to action to tackle world’s leading cause of death

A team of Australian drug researchers from Monash University, The University of Sydney and La Trobe University have led a global call to action to accelerate new approaches for cardiovascular disease (CVD) drug solutions. CVD is the leading cause of
Portrait of Professor Jonathan Baell

MIPS and WEHI granted patent for invention to help tackle cancer

An invention developed by a team of researchers from the Monash Institute of Pharmaceutical Sciences and The Walter and Eliza Hall Institute of Medical Research has been granted patent by The European Patent Office and The United States Patent and

Monash University researchers discover potential therapeutic target to reduce diabetes-induced heart failure

Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with The Baker Heart and Diabetes Institute, have discovered a potential therapeutic target which could reduce heart failure and may improve the quality of

New study finds that age and frailty considerably impact prescribing strategies for people with Type 2 Diabetes

A new study led by Monash University has - for the first time - investigated how age, frailty and dementia predict hospital discharge prescribing for people with Type 2 Diabetes (T2D), with the researchers finding that people aged 80+ are

Monash University retains its spot as #2 in the world for Pharmacy and Pharmacology

The 2021 QS World University Rankings by Subject, released today, ranked Monash University number two in the world for Pharmacy and Pharmacology for the second year running.
lymphatic

Monash University and PureTech Health develop novel technology platform that targets drugs to the lymphatics and lymph nodes

Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and PureTech Health (LSE: PRTC, Nasdaq: PRTC) have developed a novel technology platform that directly targets gut lymphatics and has great potential to enhance the utility of

Researchers from Monash University make a breakthrough discovery into how migraines are triggered

World first: Researchers from Monash University have harnessed cutting-edge technology to discover the progression of molecular events that lead to migraine – something that, until now, has remained a mystery.

Collaboration between Monash and Auckland Universities find obesity drug could treat severe acute diseases

Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with researchers at the Surgical and Translational Research (STaR) Centre at the University of Auckland, have found that a common medication used to treat